These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36736917)

  • 1. Real-World Comparative Safety and Effectiveness of Irreversible Electroporation and High-Intensity Focused Ultrasound for Prostate Cancer Ablation.
    Cribbs KA; Manning EF; Zhou J; Lahue BJ; Polascik TJ
    Urology; 2023 Apr; 174():7-17. PubMed ID: 36736917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
    Blazevski A; Scheltema MJ; Yuen B; Masand N; Nguyen TV; Delprado W; Shnier R; Haynes AM; Cusick T; Thompson J; Stricker P
    Eur Urol Oncol; 2020 Jun; 3(3):283-290. PubMed ID: 31103721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryoablation, high-intensity focused ultrasound, irreversible electroporation, and vascular-targeted photodynamic therapy for prostate cancer: a systemic review and meta-analysis.
    Guo RQ; Guo XX; Li YM; Bie ZX; Li B; Li XG
    Int J Clin Oncol; 2021 Mar; 26(3):461-484. PubMed ID: 33387088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of Oncological and Functional Outcomes Between Primary Whole-Gland Cryoablation and High-Intensity Focused Ultrasound for Localized Prostate Cancer.
    Liu YY; Chiang PH
    Ann Surg Oncol; 2016 Jan; 23(1):328-34. PubMed ID: 26088651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).
    Blazevski A; Amin A; Scheltema MJ; Balakrishnan A; Haynes AM; Barreto D; Cusick T; Thompson J; Stricker PD
    World J Urol; 2021 Apr; 39(4):1107-1114. PubMed ID: 32488359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort.
    Dickinson L; Arya M; Afzal N; Cathcart P; Charman SC; Cornaby A; Hindley RG; Lewi H; McCartan N; Moore CM; Nathan S; Ogden C; Persad R; van der Meulen J; Weir S; Emberton M; Ahmed HU
    Eur Urol; 2016 Oct; 70(4):668-674. PubMed ID: 26951947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal irreversible electroporation as primary treatment for localized prostate cancer.
    van den Bos W; Scheltema MJ; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
    BJU Int; 2018 May; 121(5):716-724. PubMed ID: 28796935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Whole-Gland High-Intensity Focused Ultrasound vs Whole-Gland High-Intensity Focused Ultrasound for Management of Localized Prostate Cancer: 1-Year Oncological and Functional Outcomes.
    Lei Y; Zanker P; Yildiz S; Hancke K; Seidl D; Koch O; Schwentner C; Mundhenk J
    J Endourol; 2019 Feb; 33(2):100-106. PubMed ID: 30526029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement.
    Deivasigamani S; Kotamarti S; Rastinehad AR; Salas RS; de la Rosette JJMCH; Lepor H; Pinto P; Ahmed HU; Gill I; Klotz L; Taneja SS; Emberton M; Lawrentschuk N; Wysock J; Feller JF; Crouzet S; Kumar M P; Seguier D; Adams ES; Michael Z; Abreu A; Jack Tay K; Ward JF; Shinohara K; Katz AE; Villers A; Chin JL; Stricker PD; Baco E; Macek P; Ahmad AE; Chiu PKF; Crawford ED; Rogers CG; Futterer JJ; Rais-Bahrami S; Robertson CN; Hadaschik B; Marra G; Valerio M; Chong KT; Kasivisvanathan V; Tan WP; Lomas D; Walz J; Guimaraes GC; Mertziotis NI; Becher E; Finelli A; Kasraeian A; Lebastchi AH; Vora A; Rosen MA; Bakir B; Arcot R; Yee S; Netsch C; Meng X; de Reijke TM; Tan YG; Regusci S; Benjamin TGR; Olivares R; Noureldin M; Bianco FJ; Sivaraman A; Kim FJ; Given RW; Dason S; Sheetz TJ; Shoji S; Schulman A; Royce P; Shah TT; Scionti S; Salomon G; Laguna P; Tourinho-Barbosa R; Aminsharifi A; Cathelineau X; Gontero P; Stabile A; Grummet J; Ledbetter L; Graton M; Stephen Jones J; Polascik TJ;
    Eur Urol; 2023 Dec; 84(6):547-560. PubMed ID: 37419773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation.
    Ramsay CR; Adewuyi TE; Gray J; Hislop J; Shirley MD; Jayakody S; MacLennan G; Fraser C; MacLennan S; Brazzelli M; N'Dow J; Pickard R; Robertson C; Rothnie K; Rushton SP; Vale L; Lam TB
    Health Technol Assess; 2015 Jul; 19(49):1-490. PubMed ID: 26140518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Location of residual cancer after transrectal high-intensity focused ultrasound ablation for clinically localized prostate cancer.
    Boutier R; Girouin N; Cheikh AB; Belot A; Rabilloud M; Gelet A; Chapelon JY; Rouvière O
    BJU Int; 2011 Dec; 108(11):1776-81. PubMed ID: 21711432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage high-intensity focused ultrasound for locally recurrent prostate cancer after low-dose-rate brachytherapy: oncological and functional outcomes.
    Hostiou T; Gelet A; Chapelon JY; Rouvière O; Mège-Lechevalier F; Lafon C; Tonoli-Catez H; Badet L; Crouzet S
    BJU Int; 2019 Nov; 124(5):746-757. PubMed ID: 31148367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
    Scheltema MJ; van den Bos W; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
    BJU Int; 2017 Nov; 120 Suppl 3():51-58. PubMed ID: 28834167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIFU focal therapy for prostate cancer using intraoperatory contrast enhanced ultrasound.
    Claros OR; Tourinho-Barbosa RR; Carneiro A; Collura-Merlier S; Macek P; Lanz C; Cathala N; Prapotnich D; Mombet A; Sanchez-Salas R; Cathelineau X
    Arch Esp Urol; 2019 Oct; 72(8):825-830. PubMed ID: 31579041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer.
    Warmuth M; Johansson T; Mad P
    Eur Urol; 2010 Dec; 58(6):803-15. PubMed ID: 20864250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer.
    Cordeiro ER; Cathelineau X; Thüroff S; Marberger M; Crouzet S; de la Rosette JJ
    BJU Int; 2012 Nov; 110(9):1228-42. PubMed ID: 22672199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer.
    Zhang K; Stricker P; Löhr M; Stehling M; Suberville M; Cussenot O; Lunelli L; Ng CF; Teoh J; Laguna P; de la Rosette J
    Prostate Cancer Prostatic Dis; 2024 Sep; 27(3):525-530. PubMed ID: 38195916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
    Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ
    BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer.
    van Riel LAMJG; Geboers B; Kabaktepe E; Blazevski A; Reesink DJ; Stijns P; Stricker PD; Casanova J; Dominguez-Escrig JL; de Reijke TM; Scheltema MJ; Oddens JR
    BJU Int; 2022 Nov; 130(5):611-618. PubMed ID: 35474600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study.
    Yaxley WJ; Gianduzzo T; Kua B; Oxford R; Yaxley JW
    Investig Clin Urol; 2022 May; 63(3):285-293. PubMed ID: 35534217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.